Intellia Therapeutics (NTLA) Financials

$11.35 -0.25 (-2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$11.42 +0.08 (+0.66%)

As of 05:50 PM Eastern

Annual Income Statements for Intellia Therapeutics

This table shows Intellia Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-12	-32	-68	-85	-100	-134	-268	-474	-481	-519
Consolidated Net Income / (Loss)	-12	-32	-68	-85	-100	-134	-268	-474	-481	-519
Net Income / (Loss) Continuing Operations	-12	-32	-68	-85	-99	-134	-270	-474	-477	-518
Total Pre-Tax Income	-13	-32	-68	-85	-99	-134	-270	-474	-477	-518
Total Operating Income	-13	-32	-70	-91	-106	-137	-268	-458	-515	-534
Total Gross Profit	6.04	16	26	30	43	58	33	52	36	58
Total Revenue	6.04	16	26	30	43	58	33	52	36	58
Operating Revenue	6.04	16	26	30	43	58	33	52	36	58
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	19	49	96	121	149	195	301	510	552	592
Selling, General & Admin Expense	8.28	17	28	32	41	44	71	90	116	126
Research & Development Expense	11	32	68	89	108	150	230	420	435	466
Other Special Charges / (Income)	-	-	-	-	-	0.00	0.00	-	0.10	0.00
Total Other Income / (Expense), net	0.00	0.53	2.01	5.50	7.12	2.35	-2.21	-16	38	16
Interest & Investment Income	0.00	0.53	2.01	5.53	6.84	2.35	-0.04	-2.54	34	15
Other Income / (Expense), net	-	0.00	0.00	-0.03	0.29	0.00	-2.17	-13	3.64	0.73
Basic Earnings per Share	($51.02)	($1.42)	($1.88)	($1.98)	($2.11)	($2.40)	($3.78)	($6.16)	($5.42)	($5.25)
Weighted Average Basic Shares Outstanding	243K	22.22M	36.01M	43.07M	47.25M	55.99M	70.89M	76.97M	88.77M	98.85M
Diluted Earnings per Share	($51.02)	($1.42)	($1.88)	($1.98)	($2.11)	($2.40)	($3.78)	($6.16)	($5.42)	($5.25)
Weighted Average Diluted Shares Outstanding	243K	22.22M	36.01M	43.07M	47.25M	55.99M	70.89M	76.97M	88.77M	98.85M
Weighted Average Basic & Diluted Shares Outstanding	243K	22.22M	36.01M	43.07M	47.25M	55.99M	70.89M	88.02M	96.11M	103.52M

This table shows Intellia Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-113	-113	-103	-124	-122	-132	-107	-147	-136	-129	-114
Consolidated Net Income / (Loss)	-113	-113	-103	-124	-122	-132	-107	-147	-136	-129	-114
Net Income / (Loss) Continuing Operations	-113	-113	-103	-125	-122	-128	-108	-147	-136	-128	-114
Total Pre-Tax Income	-113	-113	-103	-125	-122	-128	-108	-147	-136	-128	-114
Total Operating Income	-106	-110	-112	-132	-131	-140	-114	-139	-145	-136	-121
Total Gross Profit	13	14	13	14	12	-1.92	29	6.96	9.11	13	17
Total Revenue	13	14	13	14	12	-1.92	29	6.96	9.11	13	17
Operating Revenue	13	14	13	14	12	-1.92	29	6.96	9.11	13	17
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	119	123	125	146	143	138	143	146	154	149	137
Selling, General & Admin Expense	22	24	27	31	29	29	31	32	31	32	29
Research & Development Expense	97	100	97	115	114	109	112	114	123	117	108
Total Other Income / (Expense), net	-7.70	-2.71	8.83	7.46	9.18	12	5.75	-8.14	9.06	8.49	6.93
Interest & Investment Income	0.11	2.11	8.93	8.65	8.88	7.73	6.57	-7.93	9.06	7.55	6.48
Other Income / (Expense), net	-7.81	-4.81	-0.10	-1.19	0.30	4.63	-0.82	-0.21	0.00	0.94	0.45
Basic Earnings per Share	($1.49)	($1.38)	($1.17)	($1.40)	($1.38)	($1.47)	($1.12)	($1.52)	($1.34)	($1.27)	($1.10)
Weighted Average Basic Shares Outstanding	76.05M	76.97M	87.77M	88.19M	88.65M	88.77M	95.50M	96.98M	101.00M	98.85M	103.50M
Diluted Earnings per Share	($1.49)	($1.38)	($1.17)	($1.40)	($1.38)	($1.47)	($1.12)	($1.52)	($1.34)	($1.27)	($1.10)
Weighted Average Diluted Shares Outstanding	76.05M	76.97M	87.77M	88.19M	88.65M	88.77M	95.50M	96.98M	101.00M	98.85M	103.50M
Weighted Average Basic & Diluted Shares Outstanding	78.68M	88.02M	88.14M	88.49M	89.55M	96.11M	96.48M	101.58M	101.85M	103.52M	103.58M

This table details how cash moves in and out of Intellia Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	66	197	68	-282	5.82	107	-39	410	-295	-38
Net Cash From Operating Activities	-1.76	36	-65	-61	-103	-50	-225	-333	-394	-349
Net Cash From Continuing Operating Activities	-1.76	36	-65	-61	-96	-50	-225	-333	-394	-349
Net Income / (Loss) Continuing Operations	-12	-32	-68	-85	-100	-134	-268	-474	-481	-519
Consolidated Net Income / (Loss)	-12	-32	-68	-85	-100	-134	-268	-474	-481	-519
Depreciation Expense	0.33	1.10	2.99	4.46	5.59	6.31	6.89	7.57	8.98	10
Amortization Expense	-	0.00	0.00	-0.68	3.73	0.54	7.60	4.00	-26	-18
Non-Cash Adjustments To Reconcile Net Income	1.32	6.73	15	17	21	26	61	183	175	187
Changes in Operating Assets and Liabilities, net	8.99	60	-16	3.18	-26	51	-32	-54	-71	-9.59
Net Cash From Investing Activities	-2.55	-6.17	-10	-261	25	-214	-551	160	-31	126
Net Cash From Continuing Investing Activities	-2.55	-6.17	-10	-261	25	-214	-551	160	-31	126
Purchase of Property, Plant & Equipment	-2.55	-6.17	-10	-6.36	-6.79	-3.59	-13	-14	-14	-5.78
Acquisitions	-	-	-	-	-	-	0.00	-45	0.00	0.00
Purchase of Investments	-	0.00	0.00	-255	-297	-474	-1,021	-429	-904	-936
Sale of Property, Plant & Equipment	-	0.00	0.00	0.13	0.00	0.00	0.00	0.15	0.00	0.00
Sale and/or Maturity of Investments	-	-	0.00	0.00	329	263	486	648	887	1,067
Net Cash From Financing Activities	70	167	143	40	76	372	737	583	130	186
Net Cash From Continuing Financing Activities	70	167	143	40	76	372	737	583	130	186
Issuance of Common Equity	0.00	171	142	30	73	360	696	568	124	180
Other Financing Activities, net	-1.10	-0.60	1.16	11	3.09	12	41	15	6.60	5.86

This table details how cash moves in and out of Intellia Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-6.91	386	-229	-122	-2.78	59	-55	-41	-10	69	-55
Net Cash From Operating Activities	-79	-90	-109	-90	-101	-93	-121	-58	-85	-85	-149
Net Cash From Continuing Operating Activities	-79	-90	-109	-90	-101	-93	-121	-58	-85	-85	-149
Net Income / (Loss) Continuing Operations	-113	-113	-103	-124	-122	-132	-107	-147	-136	-129	-114
Consolidated Net Income / (Loss)	-113	-113	-103	-124	-122	-132	-107	-147	-136	-129	-114
Depreciation Expense	1.95	2.03	2.05	2.17	2.29	2.47	2.51	2.60	2.61	2.57	2.50
Amortization Expense	0.82	-1.25	-4.57	-7.10	-7.92	-6.31	-5.29	-4.65	-4.28	-3.60	-2.28
Non-Cash Adjustments To Reconcile Net Income	33	35	38	48	45	45	24	66	48	49	31
Changes in Operating Assets and Liabilities, net	-0.98	-13	-41	-9.69	-18	-1.75	-35	25	4.86	-4.38	-66
Net Cash From Investing Activities	48	-30	-122	-35	80	46	5.90	-24	-7.71	152	94
Net Cash From Continuing Investing Activities	48	-30	-122	-35	80	46	5.90	-24	-7.71	152	94
Purchase of Property, Plant & Equipment	-4.24	-3.91	-3.83	-4.30	-4.33	-1.52	-2.51	-1.01	-1.28	-0.98	-0.74
Purchase of Investments	-161	-236	-382	-243	-129	-150	-260	-301	-206	-169	-83
Sale and/or Maturity of Investments	213	210	264	213	213	197	268	278	200	322	178
Net Cash From Financing Activities	24	506	2.22	2.52	19	106	60	41	82	2.32	0.00
Net Cash From Continuing Financing Activities	24	506	2.22	2.52	19	106	60	41	82	2.32	0.00
Issuance of Common Equity	23	505	1.47	2.05	15	105	58	40	80	1.29	0.00
Other Financing Activities, net	0.72	0.53	0.76	0.47	4.38	1.00	1.96	1.18	1.70	1.03	0.00

This table presents Intellia Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	82	299	376	347	334	676	1,294	1,520	1,301	1,191
Total Current Assets	78	281	355	325	289	617	769	1,217	998	640
Cash & Equivalents	76	273	341	59	57	160	123	524	227	189
Short-Term Investments	-	-	0.00	255	223	437	625	669	685	412
Accounts Receivable	1.00	6.45	10	7.55	4.62	2.13	2.03	3.77	36	8.52
Prepaid Expenses	0.81	1.79	3.68	3.37	5.14	17	19	20	50	30
Plant, Property, & Equipment, net	2.71	11	15	17	18	16	21	28	33	27
Total Noncurrent Assets	1.81	7.04	6.13	5.28	27	44	504	275	270	524
Long-Term Investments	-	-	-	0.00	4.75	4.75	425	142	155	304
Other Noncurrent Operating Assets	1.81	7.04	6.13	5.28	22	39	79	133	115	219
Total Liabilities & Shareholders' Equity	82	299	376	347	334	676	1,294	1,520	1,301	1,191
Total Liabilities	15	89	76	69	64	149	254	285	251	319
Total Current Liabilities	11	31	31	41	36	64	126	127	115	111
Accounts Payable	1.36	4.65	2.17	2.71	3.94	10	9.65	5.15	7.45	15
Accrued Expenses	2.79	5.90	8.00	11	13	26	43	61	67	55
Current Deferred Revenue	6.55	20	21	27	13	23	64	44	22	21
Other Current Liabilities	-	-	-	0.00	5.75	5.70	9.11	17	19	20
Total Noncurrent Liabilities	4.09	58	44	29	29	85	128	158	136	208
Noncurrent Deferred Revenue	3.77	58	44	29	16	51	63	20	39	18
Other Noncurrent Operating Liabilities	0.32	0.29	0.17	0.01	13	34	65	138	97	190
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-21	210	301	278	270	527	1,040	1,236	1,050	872
Total Preferred & Common Equity	-21	210	301	278	270	527	1,040	1,236	1,050	872
Total Common Equity	-21	210	301	278	270	527	1,040	1,236	1,050	872
Common Stock	0.74	263	422	479	570	962	1,746	2,420	2,711	3,049
Retained Earnings	-22	-54	-121	-201	-301	-435	-703	-1,177	-1,658	-2,177
Accumulated Other Comprehensive Income / (Loss)	-	-	0.00	-0.03	0.26	0.00	-2.63	-7.46	-2.26	0.61

This table presents Intellia Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	1,110	1,084	1,418	1,323	1,243	1,260	1,192	1,173	986
Total Current Assets	895	859	964	940	893	884	757	711	551
Cash & Equivalents	148	141	294	172	168	172	131	120	127
Short-Term Investments	726	687	639	736	687	619	560	538	377
Accounts Receivable	2.85	4.02	4.91	5.06	6.49	36	12	8.85	11
Prepaid Expenses	18	27	25	26	32	56	54	44	37
Plant, Property, & Equipment, net	26	27	32	33	34	32	30	29	25
Total Noncurrent Assets	189	199	423	350	316	343	404	434	410
Long-Term Investments	115	98	294	227	197	233	299	333	272
Other Noncurrent Operating Assets	74	101	128	124	119	110	105	100	138
Total Liabilities & Shareholders' Equity	1,110	1,084	1,418	1,323	1,243	1,260	1,192	1,173	986
Total Liabilities	230	260	227	218	206	223	220	211	206
Total Current Liabilities	124	131	103	100	92	98	105	106	113
Accounts Payable	7.52	4.38	6.89	12	3.55	14	19	13	12
Accrued Expenses	45	58	45	50	58	43	45	51	41
Current Deferred Revenue	62	55	35	22	13	22	22	22	21
Other Current Liabilities	9.57	14	16	17	17	19	19	19	39
Total Noncurrent Liabilities	106	128	124	119	114	126	115	105	94
Noncurrent Deferred Revenue	35	26	14	13	13	33	28	23	13
Other Noncurrent Operating Liabilities	71	103	110	106	101	92	87	82	80
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	881	825	1,191	1,105	1,037	1,036	971	963	780
Total Preferred & Common Equity	881	825	1,191	1,105	1,037	1,036	971	963	780
Total Common Equity	881	825	1,191	1,105	1,037	1,036	971	963	780
Common Stock	1,841	1,898	2,474	2,513	2,567	2,803	2,885	3,008	3,071
Retained Earnings	-951	-1,064	-1,280	-1,404	-1,526	-1,766	-1,913	-2,049	-2,292
Accumulated Other Comprehensive Income / (Loss)	-9.55	-9.37	-2.68	-3.87	-3.57	-0.95	-1.16	3.30	1.06

This table displays calculated financial ratios and metrics derived from Intellia Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	172.65%	58.49%	16.53%	41.63%	34.55%	-43.01%	57.69%	-30.40%	59.55%
EBITDA Growth	0.00%	-137.41%	-114.33%	-30.87%	-11.09%	-34.07%	-96.96%	-80.05%	-14.89%	-2.36%
EBIT Growth	0.00%	-139.83%	-116.28%	-30.69%	-16.70%	-28.76%	-97.70%	-74.67%	-8.48%	-4.28%
NOPAT Growth	0.00%	-139.83%	-116.28%	-30.64%	-17.06%	-28.41%	-96.11%	-71.05%	-12.47%	-3.68%
Net Income Growth	0.00%	-155.17%	-113.51%	-26.35%	-16.63%	-34.86%	-99.58%	-77.01%	-1.48%	-7.86%
EPS Growth	0.00%	97.22%	-32.39%	-5.32%	-6.57%	-13.74%	-57.50%	-62.96%	12.01%	3.14%
Operating Cash Flow Growth	0.00%	2,148.16%	-280.77%	6.16%	-68.54%	51.65%	-350.85%	-48.11%	-18.24%	11.47%
Free Cash Flow Firm Growth	0.00%	0.00%	-322.70%	5.96%	-42.12%	63.39%	-267.11%	-174.98%	-24.98%	19.61%
Invested Capital Growth	0.00%	-647.36%	36.61%	9.84%	59.63%	-414.34%	-77.88%	25.57%	83.33%	-105.47%
Revenue Q/Q Growth	0.00%	31.36%	4.15%	4.15%	7.63%	-6.96%	23.36%	1.40%	-29.92%	34.33%
EBITDA Q/Q Growth	0.00%	-19.46%	-25.36%	4.03%	-1.08%	-16.71%	-17.81%	-8.40%	-4.96%	0.85%
EBIT Q/Q Growth	0.00%	-19.87%	-24.96%	4.16%	-9.35%	-9.92%	-17.81%	-7.26%	-4.14%	0.34%
NOPAT Q/Q Growth	0.00%	-19.87%	-24.96%	4.19%	-9.27%	-10.19%	-16.54%	-6.92%	-6.14%	0.64%
Net Income Q/Q Growth	0.00%	-20.21%	-24.75%	5.43%	-10.20%	-11.57%	-17.06%	-7.28%	-4.06%	0.62%
EPS Q/Q Growth	0.00%	97.04%	-124.10%	9.59%	-7.65%	-5.26%	-12.50%	-4.58%	-1.69%	3.67%
Operating Cash Flow Q/Q Growth	0.00%	-19.81%	-11.81%	17.25%	-24.21%	-30.16%	-6.85%	-11.82%	-0.81%	2.20%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-10.45%	18.44%	-4.22%	-143.48%	4.23%	-16.91%	-4.09%	1.57%
Invested Capital Q/Q Growth	0.00%	12.78%	13.65%	-20.55%	-143.35%	4.19%	-27.80%	1.50%	-13.04%	-17.97%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-216.43%	-188.45%	-254.86%	-286.23%	-224.50%	-223.70%	-773.07%	-882.70%	-1,457.14%	-934.85%
Operating Margin	-221.86%	-195.15%	-266.32%	-298.58%	-246.78%	-235.51%	-810.37%	-879.04%	-1,420.51%	-923.10%
EBIT Margin	-221.86%	-195.15%	-266.32%	-298.67%	-246.11%	-235.51%	-816.92%	-904.91%	-1,410.49%	-921.84%
Profit (Net Income) Margin	-205.11%	-191.97%	-258.62%	-280.42%	-230.92%	-231.46%	-810.49%	-909.78%	-1,326.51%	-896.77%
Tax Burden Percent	92.45%	100.00%	100.00%	99.97%	100.29%	100.00%	99.20%	100.00%	100.78%	100.14%
Interest Burden Percent	100.00%	98.37%	97.11%	93.92%	93.56%	98.28%	100.02%	100.54%	93.32%	97.14%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-18.41%	-22.82%	-26.46%	-29.50%	-36.34%	-33.69%	-34.18%	-41.67%	-42.10%	-54.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-16.32%	-16.88%	-20.60%	-25.13%	-31.13%	-27.03%	-27.40%	-33.51%	-36.27%	-42.82%
Return on Assets (ROA)	-15.09%	-16.60%	-20.01%	-23.59%	-29.21%	-26.56%	-27.19%	-33.70%	-34.11%	-41.66%
Return on Common Equity (ROCE)	5.79%	-15.53%	-26.46%	-29.50%	-36.34%	-33.69%	-34.18%	-41.67%	-42.10%	-54.00%
Return on Equity Simple (ROE_SIMPLE)	58.47%	-15.08%	-22.47%	-30.71%	-36.88%	-25.47%	-25.75%	-38.38%	-45.82%	-59.52%
Net Operating Profit after Tax (NOPAT)	-9.39	-23	-49	-64	-74	-96	-187	-321	-361	-374
NOPAT Margin	-155.30%	-136.61%	-186.42%	-209.01%	-172.74%	-164.86%	-567.26%	-615.33%	-994.36%	-646.17%
Net Nonoperating Expense Percent (NNEP)	-3.97%	-5.23%	-6.14%	-6.64%	-8.38%	-8.71%	-9.05%	-12.24%	-10.03%	-14.70%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-25.96%	-34.35%	-42.89%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	137.05%	101.94%	107.31%	105.77%	95.26%	76.16%	215.10%	173.26%	321.15%	217.41%
R&D to Revenue	184.81%	193.22%	259.02%	292.81%	251.52%	259.35%	695.27%	805.78%	1,199.36%	805.69%
Operating Expenses to Revenue	321.86%	295.15%	366.32%	398.58%	346.78%	335.51%	910.37%	979.04%	1,520.79%	1,023.10%
Earnings before Interest and Taxes (EBIT)	-13	-32	-70	-91	-106	-137	-270	-472	-512	-534
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-31	-67	-87	-97	-130	-256	-460	-529	-541
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.25	2.31	2.13	2.66	6.10	8.46	2.22	2.60	1.36
Price to Tangible Book Value (P/TBV)	0.00	2.25	2.31	2.13	2.66	6.10	8.46	2.22	2.60	1.36
Price to Revenue (P/Rev)	0.00	28.64	26.56	19.47	16.64	55.42	266.22	52.67	75.27	20.52
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	12.07	13.51	9.15	10.04	45.04	230.71	27.06	45.87	4.86
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	5.51	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	6.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.13	-1.26	-1.20	-1.13	-1.09	-1.11	-1.13	-1.10	-1.05	-1.03
Leverage Ratio	1.22	1.37	1.32	1.25	1.24	1.27	1.26	1.24	1.23	1.30
Compound Leverage Factor	1.22	1.35	1.28	1.17	1.16	1.25	1.26	1.24	1.15	1.26
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	131.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-31.48%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	3.63	5.54	4.52	5.41	12.42	19.94	4.58	4.29	-1.22
Noncontrolling Interest Sharing Ratio	131.48%	31.95%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.26	9.15	11.32	8.01	8.12	9.60	6.11	9.61	8.67	5.77
Quick Ratio	7.18	9.10	11.20	7.93	7.98	9.33	5.97	9.45	8.23	5.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	32	-72	-68	-96	-35	-129	-355	-443	-357
Operating Cash Flow to CapEx	-69.03%	585.71%	-646.87%	-983.73%	-1,519.58%	-1,392.25%	-1,764.11%	-2,485.73%	-2,817.92%	-6,038.08%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.07	0.09	0.08	0.08	0.13	0.11	0.03	0.04	0.03	0.05
Accounts Receivable Turnover	6.04	4.42	3.09	3.38	7.09	17.18	15.89	17.98	1.80	2.57
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.23	2.47	2.02	1.88	2.46	3.42	1.79	2.13	1.20	1.92
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	60.39	82.55	118.27	108.05	51.52	21.24	22.97	20.31	202.37	141.81
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	60.39	82.55	118.27	108.05	51.52	21.24	22.97	20.31	202.37	141.81
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-8.46	-63	-40	-36	-15	-75	-133	-99	-17	-34
Invested Capital Turnover	-0.71	-0.46	-0.51	-0.80	-1.70	-1.29	-0.32	-0.45	-0.63	-2.29
Increase / (Decrease) in Invested Capital	0.00	-55	23	3.94	22	-60	-58	34	83	-17
Enterprise Value (EV)	0.00	199	353	279	433	2,612	7,626	1,410	1,664	282
Market Capitalization	0.00	472	694	593	717	3,214	8,799	2,745	2,731	1,188
Book Value per Share	($87.25)	$5.83	$8.33	$6.40	$5.52	$8.92	$13.98	$15.70	$11.73	$8.56
Tangible Book Value per Share	($87.25)	$5.83	$8.33	$6.40	$5.52	$8.92	$13.98	$15.70	$11.73	$8.56
Total Capital	67	210	301	278	270	527	1,040	1,236	1,050	872
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-76	-273	-341	-314	-284	-602	-1,174	-1,335	-1,067	-906
Capital Expenditures (CapEx)	2.55	6.17	10	6.23	6.79	3.59	13	13	14	5.78
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-8.89	-22	-17	-30	-26	-45	-105	-102	-29	-73
Debt-free Net Working Capital (DFNWC)	67	251	323	284	254	552	643	1,090	883	529
Net Working Capital (NWC)	67	251	323	284	254	552	643	1,090	883	529
Net Nonoperating Expense (NNE)	3.01	9.12	19	22	25	39	80	153	120	145
Net Nonoperating Obligations (NNO)	-76	-273	-341	-314	-284	-602	-1,174	-1,335	-1,067	-906
Total Depreciation and Amortization (D&A)	0.33	1.10	2.99	3.79	9.31	6.85	14	12	-17	-7.53
Debt-free, Cash-free Net Working Capital to Revenue	-147.01%	-136.46%	-65.88%	-97.44%	-60.04%	-77.78%	-318.33%	-196.43%	-80.22%	-125.27%
Debt-free Net Working Capital to Revenue	1,107.40%	1,520.58%	1,238.55%	934.50%	588.93%	952.28%	1,946.78%	2,091.75%	2,434.52%	914.03%
Net Working Capital to Revenue	1,107.40%	1,520.58%	1,238.55%	934.50%	588.93%	952.28%	1,946.78%	2,091.75%	2,434.52%	914.03%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($3.78)	($6.16)	($5.42)	($5.25)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	0.00	0.00	0.00	74.67M	76.97M	88.77M	98.85M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($3.78)	($6.16)	($5.42)	($5.25)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	0.00	0.00	0.00	74.67M	76.97M	88.77M	98.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($3.78)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	0.00	0.00	0.00	70.89M	88.02M	96.11M	103.52M
Normalized Net Operating Profit after Tax (NOPAT)	-9.39	-23	-49	-64	-74	-96	-187	-321	-361	-374
Normalized NOPAT Margin	-155.30%	-136.61%	-186.42%	-209.01%	-172.74%	-164.86%	-567.26%	-615.33%	-994.17%	-646.17%
Pre Tax Income Margin	-221.86%	-191.97%	-258.62%	-280.51%	-230.25%	-231.46%	-817.05%	-909.78%	-1,316.22%	-895.50%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-4.86%	-8.74%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Intellia Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	84.15%	5.59%	12.03%	-3.11%	-9.60%	-114.12%	129.53%	-48.82%	-24.02%	771.57%	-42.54%
EBITDA Growth	-62.80%	-45.43%	18.37%	-45.70%	-23.41%	-21.89%	-1.92%	-2.06%	-7.33%	1.84%	-2.16%
EBIT Growth	-57.84%	-38.47%	22.48%	-35.06%	-15.41%	-17.72%	-1.74%	-4.29%	-10.67%	-0.18%	-4.82%
NOPAT Growth	-46.58%	-36.90%	22.38%	-34.62%	-24.24%	-27.07%	-1.83%	-5.07%	-10.42%	2.46%	-5.97%
Net Income Growth	-58.04%	-39.60%	29.79%	-22.85%	-7.94%	-16.54%	-4.18%	-18.83%	-11.04%	2.47%	-6.42%
EPS Growth	-53.61%	-24.32%	40.31%	-5.26%	7.38%	-6.52%	4.27%	-8.57%	2.90%	13.61%	1.79%
Operating Cash Flow Growth	-20.77%	-64.44%	-37.00%	-6.15%	-29.11%	-3.54%	-10.37%	35.58%	16.32%	8.45%	-23.43%
Free Cash Flow Firm Growth	-219.23%	-5,256.36%	-526.44%	-959.35%	-129.78%	-62.52%	24.36%	36.64%	51.04%	56.82%	39.93%
Invested Capital Growth	3.44%	25.57%	71.23%	72.43%	85.47%	83.33%	131.84%	37.99%	-96.89%	-105.47%	-61.83%
Revenue Q/Q Growth	-5.45%	2.31%	-7.12%	7.84%	-11.78%	-115.99%	1,609.39%	-75.96%	30.96%	41.30%	29.15%
EBITDA Q/Q Growth	-16.36%	-3.21%	-0.40%	-20.83%	1.45%	-1.95%	17.20%	-21.00%	-3.64%	6.76%	12.02%
EBIT Q/Q Growth	-14.65%	-1.38%	2.47%	-19.16%	2.03%	-3.40%	16.90%	-22.15%	-3.96%	6.40%	11.18%
NOPAT Q/Q Growth	-7.35%	-4.32%	-1.70%	-18.20%	0.93%	-6.70%	18.51%	-21.96%	-4.12%	5.75%	11.46%
Net Income Q/Q Growth	-12.47%	-0.16%	9.07%	-19.93%	1.18%	-8.13%	18.71%	-36.80%	7.66%	5.02%	11.30%
EPS Q/Q Growth	-12.03%	7.38%	15.22%	-19.66%	1.43%	-6.52%	23.81%	-35.71%	11.84%	5.22%	13.39%
Operating Cash Flow Q/Q Growth	7.72%	-14.44%	-21.65%	17.38%	-12.24%	8.21%	-29.67%	51.78%	-45.80%	-0.42%	-74.81%
Free Cash Flow Firm Q/Q Growth	-378.07%	-43.55%	-52.95%	-0.92%	-3.70%	-1.53%	28.81%	15.46%	19.87%	10.44%	0.99%
Invested Capital Q/Q Growth	7.53%	1.50%	62.71%	18.84%	51.26%	-13.04%	171.21%	-258.07%	-54.75%	-17.97%	113.23%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-833.45%	-840.77%	-908.92%	-1,018.46%	-1,137.79%	0.00%	-403.58%	-2,031.06%	-1,607.32%	-1,060.62%	-722.54%
Operating Margin	-795.49%	-811.07%	-888.13%	-973.47%	-1,093.29%	0.00%	-394.00%	-1,998.61%	-1,588.96%	-1,059.86%	-726.57%
EBIT Margin	-854.36%	-846.53%	-888.93%	-982.23%	-1,090.82%	0.00%	-394.00%	-2,001.60%	-1,588.96%	-1,052.57%	-723.85%
Profit (Net Income) Margin	-853.53%	-835.53%	-818.07%	-909.82%	-1,019.21%	0.00%	-371.30%	-2,112.62%	-1,489.54%	-1,001.23%	-687.61%
Tax Burden Percent	100.00%	100.54%	100.00%	99.05%	100.24%	103.63%	100.00%	99.86%	100.00%	100.73%	100.40%
Interest Burden Percent	99.90%	98.17%	92.03%	93.52%	93.21%	94.28%	94.24%	105.70%	93.74%	94.43%	94.62%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,843.90%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,840.60%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2,815.10%
Return on Equity (ROE)	-45.76%	-41.67%	-40.14%	-45.68%	-49.66%	-42.10%	-43.60%	-49.02%	-52.23%	-54.00%	-28.80%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,484.04%	0.00%	0.00%	0.00%	-4,558.00%
Operating Return on Assets (OROA)	-36.30%	-31.35%	-36.28%	-42.81%	-48.51%	0.00%	-15.48%	-73.17%	-56.66%	-48.89%	-29.38%
Return on Assets (ROA)	-36.27%	-30.95%	-33.39%	-39.66%	-45.33%	0.00%	-14.59%	-77.23%	-53.11%	-46.51%	-27.90%
Return on Common Equity (ROCE)	-45.76%	-41.67%	-40.14%	-45.68%	-49.66%	-42.10%	-43.60%	-49.02%	-52.23%	-54.00%	-28.80%
Return on Equity Simple (ROE_SIMPLE)	-53.58%	0.00%	-36.15%	-41.04%	-44.58%	0.00%	-46.86%	-52.40%	-54.26%	0.00%	-67.43%
Net Operating Profit after Tax (NOPAT)	-74	-77	-78	-93	-92	-98	-80	-97	-101	-96	-85
NOPAT Margin	-556.84%	-567.75%	-621.69%	-681.43%	-765.30%	0.00%	-275.80%	-1,399.02%	-1,112.27%	-741.91%	-508.60%
Net Nonoperating Expense Percent (NNEP)	-3.68%	-2.90%	-2.14%	-2.92%	-3.08%	-2.85%	-2.45%	-4.67%	-3.36%	-3.38%	-3.31%
Return On Investment Capital (ROIC_SIMPLE)	-	-6.24%	-	-	-	-9.32%	-	-	-	-10.95%	-10.84%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	166.93%	174.07%	217.74%	225.48%	245.19%	0.00%	107.45%	456.99%	334.77%	252.01%	174.46%
R&D to Revenue	728.56%	737.01%	770.40%	847.99%	948.10%	0.00%	386.55%	1,641.61%	1,354.19%	907.85%	652.11%
Operating Expenses to Revenue	895.49%	909.24%	988.13%	1,073.47%	1,193.29%	0.00%	494.00%	2,098.61%	1,688.96%	1,159.86%	826.57%
Earnings before Interest and Taxes (EBIT)	-113	-115	-112	-134	-131	-135	-114	-139	-145	-136	-120
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-111	-114	-115	-138	-136	-139	-117	-141	-146	-137	-120
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.16	2.22	2.75	3.25	2.70	2.60	2.38	2.22	2.17	1.36	0.94
Price to Tangible Book Value (P/TBV)	5.16	2.22	2.75	3.25	2.70	2.60	2.38	2.22	2.17	1.36	0.94
Price to Revenue (P/Rev)	82.75	52.67	61.35	67.77	54.05	75.27	46.83	46.97	48.45	20.52	16.15
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	122.02	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	64.74	27.06	38.38	46.37	33.73	45.87	27.36	25.44	25.44	4.86	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.11	-1.10	-1.08	-1.07	-1.06	-1.05	-1.01	-1.02	-1.02	-1.03	-0.99
Leverage Ratio	1.25	1.24	1.22	1.23	1.25	1.23	1.20	1.21	1.21	1.30	1.24
Compound Leverage Factor	1.25	1.21	1.12	1.15	1.17	1.16	1.13	1.28	1.13	1.22	1.17
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	8.97	5.35	7.91	8.86	6.90	5.25	5.14	3.94	3.75	-0.12	-0.93
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.55	9.61	9.32	9.41	9.72	8.67	9.03	7.21	6.73	5.77	4.90
Quick Ratio	6.35	9.45	9.08	9.14	9.37	8.23	8.45	6.69	6.31	5.50	4.57
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-77	-111	-170	-172	-178	-181	-129	-109	-87	-78	-77
Operating Cash Flow to CapEx	-1,853.34%	-2,297.26%	-2,853.03%	-2,100.05%	-2,340.28%	-6,121.97%	-4,814.92%	-5,749.60%	-6,633.07%	-8,684.51%	-20,262.59%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.04	0.04	0.04	0.04	0.04	0.03	0.04	0.04	0.04	0.05	0.04
Accounts Receivable Turnover	15.78	17.98	15.95	13.41	9.85	1.80	2.55	5.29	5.62	2.57	1.94
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.21	2.13	1.93	1.80	1.71	1.20	1.65	1.45	1.38	1.92	1.59
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	23.13	20.31	22.89	27.22	37.07	202.37	143.40	69.02	65.00	141.81	187.95
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	23.13	20.31	22.89	27.22	37.07	202.37	143.40	69.02	65.00	141.81	187.95
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-101	-99	-37	-30	-15	-17	12	-19	-29	-34	4.50
Invested Capital Turnover	-0.50	-0.45	-0.65	-0.76	-0.90	-0.63	-4.17	-1.89	-1.98	-2.29	5.59
Increase / (Decrease) in Invested Capital	3.59	34	92	79	86	83	49	11	-14	-17	-7.29
Enterprise Value (EV)	3,328	1,410	2,053	2,459	1,746	1,664	1,439	1,169	1,096	282	-39
Market Capitalization	4,254	2,745	3,280	3,594	2,798	2,731	2,464	2,159	2,087	1,188	736
Book Value per Share	$10.85	$15.70	$13.53	$12.54	$11.72	$11.73	$10.85	$10.07	$9.48	$8.56	$7.53
Tangible Book Value per Share	$10.85	$15.70	$13.53	$12.54	$11.72	$11.73	$10.85	$10.07	$9.48	$8.56	$7.53
Total Capital	825	1,236	1,191	1,105	1,037	1,050	1,036	971	963	872	780
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-926	-1,335	-1,228	-1,135	-1,052	-1,067	-1,024	-990	-991	-906	-775
Capital Expenditures (CapEx)	4.24	3.91	3.83	4.30	4.33	1.52	2.51	1.01	1.28	0.98	0.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-100	-102	-73	-68	-53	-29	-5.16	-39	-53	-73	-65
Debt-free Net Working Capital (DFNWC)	728	1,090	860	840	802	883	786	652	605	529	439
Net Working Capital (NWC)	728	1,090	860	840	802	883	786	652	605	529	439
Net Nonoperating Expense (NNE)	39	36	25	31	30	34	28	50	34	33	30
Net Nonoperating Obligations (NNO)	-926	-1,335	-1,228	-1,135	-1,052	-1,067	-1,024	-990	-991	-906	-775
Total Depreciation and Amortization (D&A)	2.77	0.78	-2.52	-4.93	-5.63	-3.84	-2.77	-2.05	-1.67	-1.04	0.22
Debt-free, Cash-free Net Working Capital to Revenue	-195.28%	-196.43%	-136.99%	-128.79%	-102.86%	-80.22%	-9.81%	-84.73%	-122.77%	-125.27%	-142.53%
Debt-free Net Working Capital to Revenue	1,415.93%	2,091.75%	1,608.77%	1,583.30%	1,548.42%	2,434.52%	1,494.43%	1,418.67%	1,404.68%	914.03%	962.93%
Net Working Capital to Revenue	1,415.93%	2,091.75%	1,608.77%	1,583.30%	1,548.42%	2,434.52%	1,494.43%	1,418.67%	1,404.68%	914.03%	962.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.49)	($1.38)	($1.17)	($1.40)	($1.38)	($1.47)	($1.12)	($1.52)	($1.34)	($1.27)	($1.10)
Adjusted Weighted Average Basic Shares Outstanding	76.05M	76.97M	87.77M	88.19M	88.65M	88.77M	95.50M	96.98M	101.00M	98.85M	103.50M
Adjusted Diluted Earnings per Share	($1.49)	($1.38)	($1.17)	($1.40)	($1.38)	($1.47)	($1.12)	($1.52)	($1.34)	($1.27)	($1.10)
Adjusted Weighted Average Diluted Shares Outstanding	76.05M	76.97M	87.77M	88.19M	88.65M	88.77M	95.50M	96.98M	101.00M	98.85M	103.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	78.68M	88.02M	88.14M	88.49M	89.55M	96.11M	96.48M	101.58M	101.85M	103.52M	103.58M
Normalized Net Operating Profit after Tax (NOPAT)	-74	-77	-78	-93	-92	-98	-80	-97	-101	-96	-85
Normalized NOPAT Margin	-556.84%	-567.75%	-621.69%	-681.43%	-765.30%	0.00%	-275.80%	-1,399.02%	-1,112.27%	-741.91%	-508.60%
Pre Tax Income Margin	-853.53%	-831.02%	-818.07%	-918.57%	-1,016.74%	0.00%	-371.30%	-2,115.61%	-1,489.54%	-993.93%	-684.89%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

Intellia Therapeutics (NASDAQ: NTLA) has shown several key financial trends over the past four years based on the quarterly financial statements analyzed up to Q1 2025:

Operating revenue increased notably from around $12.6 million in Q1 2023 to approximately $16.6 million in Q1 2025, indicating top-line growth potential.
Total gross profit consistently equals total revenue due to zero reported cost of revenue, highlighting the company's product/service structure.
The company maintains a substantial cash and short-term investment position, with total current assets at approximately $551 million in Q1 2025.
Capital investments in property, plant, and equipment have remained steady around $25 million to $32 million, supporting operational capacity.
Net income remains negative every quarter over the last four years, but the net loss has been relatively stable around -$103 million to -$114 million in recent quarters.
Research and Development expenses are consistently high, ranging from about $90 million to over $120 million quarterly, which is typical for a biotech company at clinical and development stages.
Operating expenses remain high relative to revenue, typically exceeding $130 million per quarter, which pressures operating income into losses.
Net cash from operating activities remains negative each quarter, indicating ongoing consumption of cash to fund operations without positive cash flow generation.
Equity has decreased over time due to accumulating losses, dropping from over $1.19 billion in Q1 2023 to about $780 million in Q1 2025, reflecting erosion of retained earnings.
Diluted earnings per share have consistently been negative and worsening from about -$1.17 in Q1 2023 to around -$1.1 in Q1 2025, indicating ongoing shareholder dilution and losses.

Summary: Intellia Therapeutics continues to operate at a loss with no net profitability yet, consistent with its biotech development stage. Top-line revenue growth is evident but modest compared to high R&D and operating expenses. Strong cash and investment balances position the company to continue funding operations but investor caution is warranted given persistent losses and negative cash flow from operations over the last several years. The company's focus on R&D investment reflects its growth strategy in gene-editing therapeutics but profitability and cash flow generation remain key hurdles ahead.

08/29/25 03:10 PM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About Intellia Therapeutics' Financials

When does Intellia Therapeutics' financial year end?

According to the most recent income statement we have on file, Intellia Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Intellia Therapeutics' net income changed over the last 9 years?

Intellia Therapeutics' net income appears to be on an upward trend, with a most recent value of -$519.02 million in 2024, rising from -$12.40 million in 2015. The previous period was -$481.19 million in 2023. View Intellia Therapeutics' forecast to see where analysts expect Intellia Therapeutics to go next.

What is Intellia Therapeutics' operating income?

Intellia Therapeutics' total operating income in 2024 was -$534.26 million, based on the following breakdown:

Total Gross Profit: $57.88 million
Total Operating Expenses: $592.14 million

How has Intellia Therapeutics' revenue changed over the last 9 years?

Over the last 9 years, Intellia Therapeutics' total revenue changed from $6.04 million in 2015 to $57.88 million in 2024, a change of 857.6%.

How much debt does Intellia Therapeutics have?

Intellia Therapeutics' total liabilities were at $319.06 million at the end of 2024, a 27.2% increase from 2023, and a 2,058.3% increase since 2015.

How much cash does Intellia Therapeutics have?

In the past 9 years, Intellia Therapeutics' cash and equivalents has ranged from $57.23 million in 2019 to $523.51 million in 2022, and is currently $189.18 million as of their latest financial filing in 2024.

How has Intellia Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Intellia Therapeutics' book value per share changed from -87.25 in 2015 to 8.56 in 2024, a change of -109.8%.

Related Companies

This page (NASDAQ:NTLA) was last updated on 8/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Financials

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About Intellia Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellia Therapeutics (NTLA) Financials

Annual Income Statements for Intellia Therapeutics

Quarterly Income Statements for Intellia Therapeutics

Annual Cash Flow Statements for Intellia Therapeutics

Quarterly Cash Flow Statements for Intellia Therapeutics

Annual Balance Sheets for Intellia Therapeutics

Quarterly Balance Sheets for Intellia Therapeutics

Annual Metrics And Ratios for Intellia Therapeutics

Quarterly Metrics And Ratios for Intellia Therapeutics

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About Intellia Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools